All of that said, and as always, remember to take everything here with a grain of salt. Not only is all the information here from an unofficial rumor, but it is also subject to change that could ...

GameSpot may get a commission from retail offers. In an interview with Variety, spokesperson Alan Lewis has revealed that development on the Switch 2 version is paused. "We made the difficult decision ...

A new survey from the Game Developers Conference reveals how many developers feel about the technology. A new survey from the Game Developers Conference reveals how many developers feel about the ...

GameSpot may get a commission from retail offers. According to Insider Gaming, "Beyond Good and Evil 2 is still in active development, at least for the time being." The original Beyond Good and Evil ...

Nearly 35 years after its release, James Cameron’s action masterpiece Terminator 2: Judgement Day is being remade in board game form. Bitmap Bureau released the short but excellent Terminator 2D: No ...

After a long, action-packed year of video game releases in 2025, the video games industry is set to pack an even bigger punch in 2026. Later in the year will see major releases for Nintendo, Sony, and ...

Marc Santos is a Guides Staff Writer from the Philippines with a BA in Communication Arts and over six years of experience in writing gaming news and guides. He plays just about everything, from ...

Derek's love of games came at an early age when his parents first brought home the Nintendo Entertainment System. From then on, countless nights were spent hunting ducks, stomping turtles, exploring ...

Helldivers 2 is getting its next premium Warbond on December 2, bringing new weapons, armor sets, and everything else you need to stomp some bugs. The Python Commandos Warbond seems inspired by the ...

While survival-shooter STALKER 2: Heart of Chornobyl recently exited Game Pass, the developers posted a message thanking the teams at Xbox for support. When you purchase through links on our site, we ...

After dropping so-so early-stage results on its dual GLP-1/GLP-2 agonist earlier this year, fierce competition in the obesity treatment scene has persuaded Zealand Pharma to aim its development engine ...